Company Filing History:
Years Active: 2004-2006
Title: **Innovative Contributions of Marci Crandall in Pharmacological Research**
Introduction
Marci Crandall, an accomplished inventor based in Middletown, CT, has made significant strides in the field of pharmacological research. With a focus on GABA-modulatory compounds, she has developed innovative methods that provide insights into cognitive enhancing, anxiolytic, hypnotic, and antidepressant properties of various compounds. Her extensive research leads to important advancements in understanding and treating neurological disorders.
Latest Patents
Marci Crandall holds two patents that showcase her expertise and innovative approach. Her latest patent, titled "Methods for screening GABA-modulatory compounds for specified pharmacological activities," outlines procedures that are instrumental in assaying compounds for their various properties. The methods involve determining the in vitro efficacy and EC of the tested compounds on defined series of cloned GABA subtype receptors, consisting of specific variants of α, β, and γ subunits. This process allows for the development of an activity profile for each compound, which is crucial for understanding their potential therapeutic benefits. Additionally, the binding affinities of the compounds at GABA receptors are assessed. To enhance the research scope, the in vivo effects may also be evaluated in animal models, further validating the compounds' efficacy.
Career Highlights
Marci Crandall's career is marked by her dedication to exploring innovative methodologies in pharmacological research. Her work at Neurogen Corporation has positioned her as a leading figure in the field. Through her inventive patents, she aims to bridge the gap between laboratory research and clinical applications that can improve the quality of life for individuals facing neurological challenges.
Collaborations
Throughout her career, Marci has collaborated with other remarkable scientists, including John Tallman and Dorothy Gallagher. These collaborations enhance the research capabilities at Neurogen Corporation, allowing them to advance their understanding of GABA-modulatory compounds together. Working alongside esteemed colleagues helps foster an environment of innovation and shared knowledge.
Conclusion
In conclusion, Marci Crandall's contributions to pharmacological research through her patents and collaborations highlight her as a key innovator in the field. Her methods for screening GABA-modulatory compounds not only advance scientific understanding but also pave the way for potential therapeutic applications. As her career progresses, the impact of her work is anticipated to grow, benefiting the scientific community and society at large.